Biotech | January 22, 2022
Lannett receives USFDA safety review for biosimilar insulin glargine
Go-ahead for pivotal clinical trial which is expected to commence by March
Go-ahead for pivotal clinical trial which is expected to commence by March
Biocon has reported consolidated financial results for the period ended December 31, 2021
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Vigabatrin is an anticonvulsant. It is known to work by stopping the breakdown of a natural calming substance (GABA) in the brain
This is the company’s first partnership arrangement in China
He holds nine US patents and has published in multiple peer-reviewed journals and conferences
ICICI Direct gives a preview on the earnings narrative for Q3FY22
The stability is led by healthy demand in the domestic and emerging markets
The drug is priced at Rs 2000 for a course of 40 tablets
The transaction is expected to close in the first quarter of 2022
Subscribe To Our Newsletter & Stay Updated
